Product Pipeline / ATROSIMAB

The monovalent TNF-R1 antagonist

Lead compound for the treatment of chronic liver diseases.

Atrosimab is Baliopharm´s follow on product of the full-length antibody Atrosab and likewise specifically targets the pro-inflammatory TNF receptor 1 (TNF-R1). Atrosimab has been affinity matured and is expressed as a monovalent antibody format lacking the hinge region and the CH1 domain. The optimization process resulted in several favorable characteristics compared to Atrosab including a 3,6-fold stronger inhibition of TNF-R1 activation, a 5-fold more effective inhibition of TNF-alpha induced cell death and a 6-fold more potent inhibition of TNF-alpha mediated release of the pro-inflammatory cytokines IL-6 and IL-8. Additionally, Atrosimab has been designed to feature a longer half-life than standard Fab and scFv fragments.

Atrosimab is in early preclinical stages and the development is pursued together with Promethera Biosciences for the treatment of NASH specifically and potentially other chronic liver diseases as stand-alone therapy as well as in combination with Promethera’s cell-based medicines.